Combining Ivermectin, an FDA-approved anti-parasitic drug, with sorafenib led to a more effective reduction of HCC tumors and inhibition of mTOR/STAT3 pathway along with reduced stemness [46]. This evidence concerns the gene MTOR and hepatocellular carcinoma.